See the Notes section for the full list of authors' affiliations.
J Natl Cancer Inst. 2019 Aug 1;111(8):820-827. doi: 10.1093/jnci/djy192.
Cervical cancer is caused by persistent human papillomavirus (HPV) infection. US consensus management guidelines for a positive cervical screening result typically focus on the current screening result only. A negative testing history may alter risk of the following positive screening results, caused by a new HPV infection, and therefore its optimal management.
Women ages 30 years and older were screened with triennial HPV and cytology co-testing at Kaiser Permanente Northern California from 2003 to 2014. We estimated the subsequent 5-year risks of cervical intraepithelial neoplasia grade 3 or more severe diagnoses (CIN3+) in a cohort of 1 156 387 women following abnormal (atypical squamous cells of undetermined significance [ASC-US] or worse) cytology and/or positive HPV testing, when the test result followed 0 (n = 990 013), 1 (n = 543 986), 2 (n = 245 974), or 3 (n = 79 946) consecutive negative co-test(s). All statistical tests were two-sided.
Following 0-3 successive negative co-tests, 5-year CIN3+ risks following a positive HPV test decreased progressively from 7.2% (95% CI = 7.0% to 7.4%) to 1.5% (95% CI = 0.7% to 3.4%) (Ptrend < .001). Similarly, risks following an abnormal (ASC-US or worse) cytology result decreased from 6.6% (95% CI = 6.4% to 6.9%) to 1.1% (95% CI = 0.5% to 2.3%) (Ptrend < .001). Risks following low-grade squamous intraepithelial lesion, the risk threshold for referral to colposcopy in the United States, decreased from 5.2% (95% CI = 4.7% to 5.7%) to 0.9% (95% CI = 0.2% to 4.3%). Risks following high-grade squamous intraepithelial lesion or more severe, a specific marker for the presence of precancerous lesions, decreased from 50.0% (95% CI = 47.5% to 52.5%) to 10.0% (95% CI = 2.6% to 34.4%).
Following one or more sequential antecedent, documented negative co-tests or HPV tests, women with HPV-positive ASC-US or low-grade squamous intraepithelial lesion might have sufficiently low CIN3+ risk that they do not need colposcopy referral and might instead undergo 6-12-month surveillance for evidence of higher risk before being referred to colposcopy.
宫颈癌是由持续性人乳头瘤病毒(HPV)感染引起的。美国对阳性宫颈筛查结果的共识管理指南通常仅关注当前的筛查结果。阴性检测史可能会改变因新的 HPV 感染而导致的以下阳性筛查结果的风险,因此需要对其进行最佳管理。
在 2003 年至 2014 年期间,北加州 Kaiser Permanente 的 30 岁及以上女性采用每三年一次的 HPV 和细胞学联合检测进行筛查。我们在一个由 1156387 名女性组成的队列中估计了异常(非典型鳞状细胞意义不明[ASC-US]或更差)细胞学和/或 HPV 检测阳性后,连续阴性联合检测(co-test)结果为 0(n=990013)、1(n=543986)、2(n=245974)或 3(n=79946)次的情况下,后续 5 年宫颈上皮内瘤变 3 级及以上(CIN3+)的风险。所有统计检验均为双侧。
在连续 0-3 次阴性联合检测后,HPV 检测阳性后 5 年 CIN3+的风险从 7.2%(95%CI=7.0%至 7.4%)逐渐降低至 1.5%(95%CI=0.7%至 3.4%)(P<0.001)。同样,异常(ASC-US 或更差)细胞学结果后的风险从 6.6%(95%CI=6.4%至 6.9%)降低至 1.1%(95%CI=0.5%至 2.3%)(P<0.001)。低级别鳞状上皮内病变的风险,即美国转诊行阴道镜检查的风险阈值,从 5.2%(95%CI=4.7%至 5.7%)降低至 0.9%(95%CI=0.2%至 4.3%)。高级别鳞状上皮内病变或更严重病变的风险,即癌前病变的特定标志物,从 50.0%(95%CI=47.5%至 52.5%)降低至 10.0%(95%CI=2.6%至 34.4%)。
在一个或多个连续的先前记录的阴性联合检测或 HPV 检测之后,HPV 阳性的 ASC-US 或低级别鳞状上皮内病变的女性 CIN3+的风险可能足够低,无需转诊行阴道镜检查,而可以进行 6-12 个月的监测,以在转诊行阴道镜检查之前发现更高的风险。